BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 26661111)

  • 1. Vaginal-cuff control and toxicity results of a daily HDR brachytherapy schedule in endometrial cancer patients.
    Ríos I; Rovirosa A; Ascaso C; Valduvieco I; Herreros A; Castilla L; Sabater S; Holub K; Pahisa J; Biete A; Arenas M
    Clin Transl Oncol; 2016 Sep; 18(9):925-30. PubMed ID: 26661111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daily schedule for high-dose-rate brachytherapy in postoperative treatment of endometrial carcinoma.
    Rovirosa A; Valduvieco I; Ascaso C; Herreros A; Bautista C; Romera I; Arenas M; Pahisa J; Biete A
    Clin Transl Oncol; 2013 Feb; 15(2):111-6. PubMed ID: 22855177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can we shorten the overall treatment time in postoperative brachytherapy of endometrial carcinoma? Comparison of two brachytherapy schedules.
    Rovirosa A; Ascaso C; Arenas M; Sabater S; Herreros A; Camarasa A; Rios I; Holub K; Pahisa J; Biete A
    Radiother Oncol; 2015 Jul; 116(1):143-8. PubMed ID: 26194144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three or four fractions per week in postoperative high-dose-rate brachytherapy for endometrial carcinoma. The long-term results on vaginal relapses and toxicity.
    Valduvieco I; Rovirosa Á; Herreros A; Romera I; Ríos I; Ascaso C; Sánchez-Reyes A; Arenas M; Pahisa J; Biete A
    Clin Transl Oncol; 2013 Aug; 15(8):602-7. PubMed ID: 23263910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new short daily brachytherapy schedule in postoperative endometrial carcinoma. Preliminary results.
    Rovirosa Á; Ascaso C; Herreros A; Sánchez J; Holub K; Camarasa A; Sabater S; Oses G; García-Miguel J; Rivera Y; Arenas M
    Brachytherapy; 2017; 16(1):147-152. PubMed ID: 28029590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three or four fractions of 4-5 Gy per week in postoperative high-dose-rate brachytherapy for endometrial carcinoma.
    Rovirosa A; Ascaso C; Sánchez-Reyes A; Herreros A; Abellana R; Pahisa J; Lejarcegui JA; Biete A
    Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):418-23. PubMed ID: 20800388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative results of three short brachytherapy schedules as exclusive treatment in postoperative endometrial carcinoma.
    Rovirosa Á; Herreros A; Camacho C; Ascaso C; Sánchez J; Cortés S; Sabater S; Solà J; Torné A; Arenas M
    Brachytherapy; 2017; 16(6):1169-1174. PubMed ID: 28801116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary results of a vaginal constraint for reducing G2 late vaginal complications after postoperative brachytherapy in endometrial cancer: a prospective analysis.
    Zhang Y; Gomez G; Ascaso C; Herreros A; Fornes B; Mases J; Rochera J; Tagliaferri L; Sabater S; Torne A; Biete A; Rovirosa Á
    Clin Transl Oncol; 2022 May; 24(5):875-881. PubMed ID: 34854030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative vaginal cuff irradiation using high dose rate remote afterloading: a phase II clinical protocol.
    Noyes WR; Bastin K; Edwards SA; Buchler DA; Stitt JA; Thomadsen BR; Fowler JF; Kinsella TJ
    Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1439-43. PubMed ID: 7635785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is one brachytherapy fraction of 7 Gy similar to more fractions after external beam irradiation in postoperative endometrial carcinoma?
    Zhang Y; Ascaso C; Herreros A; Sánchez J; Del Pino M; Torné A; Li Y; Sabater S; Arenas M; Biete A; Rovirosa Á
    Clin Transl Oncol; 2020 Aug; 22(8):1295-1302. PubMed ID: 31865604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new method of anatomically conformal vaginal cuff HDR brachytherapy.
    Miller DA; Richardson S; Grigsby PW
    Gynecol Oncol; 2010 Mar; 116(3):413-8. PubMed ID: 19892389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ten-year data on 138 patients with endometrial carcinoma and postoperative vaginal brachytherapy alone: no need for external-beam radiotherapy in low and intermediate risk patients.
    Röper B; Astner ST; Heydemann-Obradovic A; Thamm R; Jacob V; Hölzel D; Schmalfeldt B; Kiechle-Bahat M; Höss C; Molls M
    Gynecol Oncol; 2007 Dec; 107(3):541-8. PubMed ID: 17884152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. American Brachytherapy Society survey regarding practice patterns of postoperative irradiation for endometrial cancer: current status of vaginal brachytherapy.
    Small W; Erickson B; Kwakwa F
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1502-7. PubMed ID: 16109462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Definitive salvage for vaginal recurrence of endometrial cancer: the impact of modern intensity-modulated-radiotherapy with image-based HDR brachytherapy and the interplay of the PORTEC 1 risk stratification.
    Vargo JA; Kim H; Houser CJ; Berhane H; Sukumvanich P; Olawaiye AB; Kelley JL; Edwards RP; Comerci JT; Huang M; Courtney-Brooks M; Beriwal S
    Radiother Oncol; 2014 Oct; 113(1):126-31. PubMed ID: 25241996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are 7.5 Gy×2 fractions more efficient than 6 Gy×3 in exclusive postoperative endometrial cancer brachytherapy? A clinical and dosimetrical analysis.
    Noorian F; Abellana R; Zhang Y; Herreros A; Baltrons C; Lancellota V; Tagliaferri L; Sabater S; Torne A; Rovirosa A
    Radiother Oncol; 2023 Dec; 189():109909. PubMed ID: 37699447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer.
    Alektiar KM; Venkatraman E; Chi DS; Barakat RR
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):111-7. PubMed ID: 15850910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of toxicity after image-guided high-dose-rate interstitial brachytherapy for gynecologic cancer.
    Lee LJ; Viswanathan AN
    Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1192-7. PubMed ID: 22592049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaginal vault brachytherapy as sole postoperative treatment for low-risk endometrial cancer.
    Chong I; Hoskin PJ
    Brachytherapy; 2008; 7(2):195-9. PubMed ID: 18358790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
    Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravaginal 1-week high-dose-rate brachytherapy alone for Stages I-II endometrial cancer.
    Martínez-Monge R; Nagore G; Cambeiro M; Garrán C; Villafranca E; Jurado M
    Brachytherapy; 2007; 6(3):195-200. PubMed ID: 17681240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.